Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Dow
McKinsey
Colorcon
Johnson and Johnson

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ATOGEPANT

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Atogepant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02848326 ↗ Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention Completed Allergan Phase 2/Phase 3 2016-09-06 This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.
NCT03700320 ↗ Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine Completed Allergan Phase 3 2018-10-08 This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.
NCT03777059 ↗ 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine Completed Allergan Phase 3 2018-12-14 To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
NCT03855137 ↗ Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine Active, not recruiting Allergan Phase 3 2019-03-11 This study will evaluate the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study includes a 12-week treatment period.
NCT03939312 ↗ Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine Completed Allergan Phase 3 2019-05-06 To evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
NCT04437433 ↗ A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine Enrolling by invitation Allergan Phase 3 2020-06-18 This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Japanese Participants with Chronic or Episodic Migraine
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Atogepant

Condition Name

Condition Name for Atogepant
Intervention Trials
Episodic Migraine 6
Chronic Migraine 5
Migraine 1
Migraine, With or Without Aura 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Atogepant
Intervention Trials
Migraine Disorders 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Atogepant

Trials by Country

Trials by Country for Atogepant
Location Trials
United States 223
Japan 49
Poland 40
China 30
France 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Atogepant
Location Trials
Florida 9
Utah 8
Texas 8
Ohio 8
Colorado 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Atogepant

Clinical Trial Phase

Clinical Trial Phase for Atogepant
Clinical Trial Phase Trials
Phase 3 9
Phase 2/Phase 3 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Atogepant
Clinical Trial Phase Trials
Completed 5
Enrolling by invitation 2
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Atogepant

Sponsor Name

Sponsor Name for Atogepant
Sponsor Trials
Allergan 11
Allergan Limited 1st Floor Marlow International, The Parkway Marlow, Buckinghamshire SL7 lYL 1
Peking University Third Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Atogepant
Sponsor Trials
Industry 11
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Medtronic
Baxter
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.